Argus
•
Sep 02, 2026
NBIX: Raising target price to $172.00
Summary
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Repligen Corporation
Sep 03, 2026
•
RGEN
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
EXEL: Raising target price to $63.00
Sep 02, 2026
•
EXEL
SRPT: Raising target price to $17.00
Sep 02, 2026
•
SRPT
ACAD: Lowering target price to $30.00
Sep 02, 2026
•
ACAD
